Pfizer, MorphoSys and Incyte Enter into Clinical Trial Colla

DGAP-News: MorphoSys AG


/ Key word: Agreement/Miscellaneous





Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® in Combination with TTI-622, a Fusion... | June 13, 2022

Related Keywords

Germany , New York , United States , United Kingdom , Planegg , Bayern , Massachusetts , Boston , Delaware , Canada , America , American , Lance Leopold , Catalina Loveman , Chris Boshoff , Christine Chiou , Jenifer Antonacci , Development Officer , Xencor Inc , Linkedin , Twitter , Nasdaq , American Society Of Hematology , Pfizer , Pfizer Inc , Public Affairs , Group Vice , Drug Administration , Pfizer Global Product Development , Exchange Commission , Youtube , Morphosys Us Inc , European Medicines Agency , Clinical Development Hematology , Incyte Enter , Clinical Trial Collaboration , Fusion Protein Directed Against , Chief Development Officer , Pfizer Global Product , Malte Peters , Morphosys Chief Research , Group Vice President , American Society , Annual Meeting , North America , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Pfizer Oncology , Breakthroughs That Change Patient , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future , Morphosy Annual Report , Morphosys Ag Stock Exchange , News , Information , Press Release , Morphosys , Key , End , Incyte , Winter , Into , Linical , Trial , Collaboration , Or , N , Combination , Ith Mor De0006632003 ,